Raily Aesthetic Medicine International Holdings Limited Provided consolidated unaudited earnings guidance for the year ended 31 December 2022. For the period, the Board expects the Group to record a revenue of approximately RMB 165 million (2021: revenue of approximately RMB 188 million) and expects to record a loss attributable to owners of the parent of approximately RMB 16 million (2021: loss of approximately RMB18 million).
Raily Aesthetic Medicine International Holdings Limited
Equities
2135
KYG7356A1215
Healthcare Facilities & Services
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.14 HKD | -7.89% | -15.66% | -70.83% |
Apr. 19 | Raily Aesthetic Medicine International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Raily Aesthetic Medicine Forecasts Wider Loss in 2023 | MT |
1st Jan change | Capi. | |
---|---|---|
-70.83% | 9.96M | |
-20.16% | 16.21B | |
+4.50% | 12.44B | |
+3.98% | 11.58B | |
+9.72% | 10.79B | |
+23.61% | 8.26B | |
-2.19% | 7.68B | |
+20.75% | 7.2B | |
+4.49% | 6.67B | |
+50.89% | 4.66B |
- Stock Market
- Equities
- 2135 Stock
- News Raily Aesthetic Medicine International Holdings Limited
- Raily Aesthetic Medicine International Holdings Limited Provides Consolidated Unaudited Earnings Guidance for the Year Ended 31 December 2022